Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SMAD2
REST API REST API
Homo sapiens
SMAD2 is differentially expressed in 359 experiments: 151 organism parts: liver, ovary, ... (149 more);, 242 disease states: normal, acute myeloid leukemia, ... (240 more);, 111 cell types 502 cell lines 56 compound treatments and 80 other conditions.
Synonyms JV18-1, MADH2, MADR2
Orthologs SMAD2 (Gallus gallus)   Q08DE0_BOVIN (Bos taurus)   SMAD2 (Gallus gallus)   smad2 (Danio rerio)   Smad2 (Rattus norvegicus)   Smad2 (Mus musculus)   ENSCING00000006188 (Ciona intestinalis)   Smox (Drosophila melanogaster)   smad2 (Xenopus laevis)   SMAD2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term zygotic specification of dorsal/ventral axis, cytosol, pattern specification process, mesoderm formation, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, intracellular, negative regulation of cell proliferation, protein complex, transcription, DNA-dependent, developmental growth, embryonic foregut morphogenesis, transforming growth factor beta receptor signaling pathway, regulation of transforming growth factor beta receptor signaling pathway, organ growth, transcription factor binding, endoderm development, positive regulation of transcription from RNA polymerase II promoter, transforming growth factor beta receptor binding, nucleus, heart development, transcription factor complex, post-embryonic development, cell fate commitment, chromatin binding, SMAD binding, nucleoplasm, gastrulation, positive regulation of transcription, DNA-dependent, embryonic pattern specification, ubiquitin protein ligase binding, positive regulation of epithelial to mesenchymal transition, regulation of binding, phosphatase binding, in utero embryonic development, response to cholesterol, pericardium development, co-SMAD binding, activin responsive factor complex, pancreas development, SMAD protein complex assembly, transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity, lung development, insulin secretion, palate development, embryonic cranial skeleton morphogenesis, response to glucose stimulus, paraxial mesoderm morphogenesis, ureteric bud development, R-SMAD binding, common-partner SMAD protein phosphorylation, type I transforming growth factor beta receptor binding, I-SMAD binding, sequence-specific DNA binding transcription factor activity, protein phosphorylation, activating transcription factor binding, intracellular signal transduction, primary miRNA processing, SMAD protein complex, anterior/posterior pattern specification
InterPro Term MAD_homology1_Dwarfin-type, SMAD_dom_Dwarfin-type, MAD_homology_MH1, Interferon_reg_factor-3
UniProt Accession Q15796, Q53XR6
Search EB-eye ENSG00000175387
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (51 experiments)

Factor Value U/D Experiments
K562
3
E-MTAB-37, E-GEOD-24147, E-GEOD-96
SW480
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
UACC812
2
E-MTAB-37, E-MTAB-62
A549
2
E-GEOD-6013, E-GEOD-3202
HCC38
2
E-MTAB-37, E-MTAB-62
496 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, E-GEOD-2822, ... (56 experiments)

Factor Value U/D Experiments
centroblast
2
E-TABM-702, E-GEOD-15271
721 B lymphoblast
2
E-TABM-145, E-AFMX-5
CD56+ NK cells
2
E-TABM-145, E-AFMX-5
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
fibroblast
2
E-GEOD-3920, E-GEOD-26672
not specified
2
E-GEOD-18811, E-GEOD-11755
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (77 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
3
E-GEOD-96, E-GEOD-5550, E-MTAB-62
acute lymphoblastic leukemia
3
E-MTAB-62, E-MTAB-37, E-GEOD-96
acute promyelocytic leukemia
3
E-GEOD-96, E-MTAB-62, E-GEOD-995
chronic lymphocytic leukemia
3
E-GEOD-2466, E-MTAB-37, E-GEOD-6691
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
236 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-TABM-782, E-GEOD-5824, ... (34 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
hydroxyurea
2
E-GEOD-571, E-GEOD-6431
Cxcl12
1
E-GEOD-7307
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
unknown
1
E-GEOD-7307
placebo
1
E-MEXP-1335
50 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
29
2
1
E-GEOD-3494
29 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-22513, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-22278, E-GEOD-10315, ... (16 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (45 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.375 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM